Results 221 to 230 of about 148,446 (303)

The Impact of Anticoagulation in Patients With Isolated Cancer‐Associated Splanchnic Vein Thrombosis: A Dual‐Center Cohort Study

American Journal of Hematology, Volume 101, Issue 6, Page 1379-1387, June 2026.
ABSTRACT Data to guide management of isolated bland cancer‐associated splanchnic vein thrombosis (CA‐SpVT) are limited. We aimed to assess the role of anticoagulation (AC) and bleeding and thrombosis in patients with CA‐SpVT. We conducted a dual‐center retrospective cohort study of adults with incident, isolated, bland CA‐SpVT from 2011 to 2020.
Abhilasha Borad, Michael Andersen Jr., Danielle Guffey, Hanqing Shang, Jun Y. Jiang, Maria J. Fernandez Turizo, Jonathan Berry, Jeffrey I. Zwicker, Rushad Patell, Ang Li   +9 more
wiley   +1 more source

Anemia as a Potent and Underrecognized Driver of Venous Thromboembolism: A Systematic Review. [PDF]

J Clin Med
Mansour GK, Alshahrani WA, Alfehaid L, Alshehri AM, Al Yami MS.   +4 more
europepmc   +1 more source

No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects

International Journal of Cancer, Volume 158, Issue 11, Page 2920-2927, 1 June 2026.
What's new? Venous thromboembolism (VTE) is common in cancer patients, with direct oral anticoagulants, including rivaroxaban, recommended as first‐line therapy. However, oral anticoagulant use is limited due to the growing use of targeted therapy and concerns about drug‐drug interactions.
Esther M. Hollander, Alessandra I. G. Buma, Jenneke Leentjens, Paddy K. C. Janssen, Michel M. van den Heuvel, David M. Burger, Berber Piet, Rob ter Heine   +7 more
wiley   +1 more source

Clinical factors associated with venous thromboembolism in multiple myeloma patients treated with daratumumab. [PDF]

Discov Med (Singap)
Subramanian NG, Aung FM, Hunzeker ZE, Patel KK, Lee HC, Jin S, Young E, Bassett RL, Rojas Hernandez CM.   +8 more
europepmc   +1 more source

Venous Thromboembolism (VTE) Risk Stratification in Otolaryngology: Socioeconomic and Subspecialty Insights

Laryngoscope Investigative Otolaryngology, Volume 11, Issue 3, June 2026.
ABSTRACT Objective Venous thromboembolism (VTE) is a leading cause of preventable perioperative mortality in otolaryngology, highlighting the urgent need for validated risk assessments such as the Caprini score to guide prophylaxis and enhance patient safety.
Corinne A. Pittman, Hudson Liu, Lovedeep Singh, Serenity G. Budd, Sabrina Heman‐Ackah, Selena E. Briggs   +5 more
wiley   +1 more source

Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin for Treating Venous Thromboembolism in Patients With Gastrointestinal Cancer. [PDF]

Cancer Med
Chang WT, Lee MC, Lin HW, Lin SH, Li YH.
europepmc   +1 more source

Assessment of Venous Thromboembolism Risk Among Patients Admitted to Intensive Care Units in Dhaka City: A Cross‐Sectional Study

Public Health Challenges, Volume 5, Issue 2, June 2026.
Nearly half of ICU patients in Dhaka City are at high risk for venous thromboembolism by Padua risk assessment model, yet only 28.57% of high‐risk patients received prophylaxis. Mandatory systematic risk assessment and LMWH protocols are urgently needed to close this preventable care gap.
Md. Shek Sady Khan, Md. Maruf Parves, Abdullah Al Noman, Pradip Kumar Sen Gupta, Md. Mojibur Rahman, Kazi Fharia Tanjim, Masuma Khatun, Muhammad Jubaer Chowdhury, Kazi Ashiqur Rahman, A K M Ferdous Rahman, Md. Sadekul Islam   +10 more
wiley   +1 more source

Venous thromboembolism prophylaxis in postacute care units: a health record review. [PDF]

Res Pract Thromb Haemost
Joo P, Qu K, Stasso J, Irani T, Chahal S, Ramsay T, Castellucci L.   +6 more
europepmc   +1 more source

Prevalence of Potentially Inappropriate Apixaban Prescribing Within a Single‐Centre Tertiary Hospital

Australasian Journal on Ageing, Volume 45, Issue 2, June 2026.
ABSTRACT Objective Apixaban is widely recommended as first line therapy for atrial fibrillation (AF) and venous thromboembolism (VTE). Despite the widespread availability of dosing guidelines, anecdotal evidence suggests clinicians do not routinely follow these recommendations. Inappropriate dose reduction is associated with suboptimal patient outcomes.
Katherine J. Creeper, Grace Lenaghan, Aaron Stockwell, Matthew Schmidt, Katharine Ingram, Andrew C. Stafford   +5 more
wiley   +1 more source

Venous thromboembolism surveillance after lung transplantation: missed events and clinical impact. [PDF]

J Thorac Dis
Miyashita Y, Kim NT, Kaihou T, Kim JT, Kurihara C.   +4 more
europepmc   +1 more source